News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Russo Rene
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/18/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 700,000 options to buy
@ $2.785, valued at
$1.9M
|
|
01/04/2023 |
4
| Russo Rene (CEO) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 350,000 options to buy
@ $2.69, valued at
$941.5k
|
|
02/24/2022 |
4
| Russo Rene (CEO AND PRESIDENT) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 150,000 options to buy
@ $12.66, valued at
$1.9M
|
|
01/04/2022 |
4/A
| Russo Rene (CEO AND PRESIDENT) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $13.83, valued at
$1.4M
|
|
12/23/2021 |
4
| Russo Rene (CEO AND PRESIDENT) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $13.83, valued at
$1.4M
|
|
10/25/2021 |
4
| Russo Rene (CEO and President) has filed a Form 4 on Xilio Therapeutics, Inc.
Txns:
| Granted 50,041 options to buy
@ $16, valued at
$800.7k
|
|
10/21/2021 |
3
| Russo Rene (CEO and President) has filed a Form 3 on Xilio Therapeutics, Inc. |
08/09/2021 |
4
| Russo Rene (Director) has filed a Form 4 on Adagio Therapeutics, Inc.
Txns:
| Granted 35,593 options to buy
@ $17, valued at
$605.1k
|
|
06/02/2021 |
4
| Russo Rene (Director) has filed a Form 4 on X4 Pharmaceuticals, Inc
Txns:
| Granted 6,000 options to buy
@ $9.5, valued at
$57k
|
|
06/11/2020 |
4
| Russo Rene (Director) has filed a Form 4 on X4 Pharmaceuticals, Inc
Txns:
| Granted 3,427 options to buy
@ $8.69, valued at
$29.8k
|
|
06/19/2019 |
4
| Russo Rene (Director) has filed a Form 4 on X4 Pharmaceuticals, Inc
Txns:
| Granted 3,427 options to buy
@ $14.75, valued at
$50.5k
|
|
03/09/2018 |
4
| Russo Rene (President and CEO) has filed a Form 4 on Arsanis, Inc.
Txns:
| Granted 160,000 options to buy
@ $17.34, valued at
$2.8M
|
|
11/15/2017 |
3
| Russo Rene (See Remarks) has filed a Form 3 on Arsanis, Inc. |
|
|